OR WAIT null SECS
November 26, 2018
ADC Biotechnology will invest downstream formulation, fill/finish capabilities, and Lock-Release conjugation technology.
November 02, 2018
Demand for highly potent APIs continues to rise.
October 17, 2018
Cambrex will create a new center of excellence for API process development and clinical supply at its High Point, NC facility and expand its API manufacturing facility in Italy.
October 15, 2018
Clovis Oncology and Lonza celebrated the grand opening of a dedicated production train at Lonza’s Visp, Switzerland site for manufacturing Rubraca (rucaparib).
October 02, 2018
Integration of new modeling and analytical tools with flow chemistry are notable trends.
September 26, 2018
The European Medicines Agency’s detection of a second nitrosamine in a sartan API is driving a deeper dive into tetrazole chemistry; root-cause investigations will now include not only valsartan and losartan, but candesartan, irbesartan, and olmesartan.
September 18, 2018
The $425-million acquisition adds formulation development and finished dosage manufacturing capabilities to Cambrex’s existing global API manufacturing network.
September 04, 2018
As it investigates the root cause of an impurity discovered in valsartan, FDA extends its studies to APIs with similar synthesis processes.
September 02, 2018
Existing software tools cannot take into account the complexity of disease.
August 02, 2018
Low-temperature chemistry enables performance of more challenging and selective chemistry.